Inhibition of c-Jun N-terminal kinase 2 expression suppresses growth and induces apoptosis of human tumor cells in a p53-dependent manner

Molecular and Cellular Biology

Volumn 20, Issue 5, 2000, Pages 1713-1722

  Potapova, Olga ^a   Gorospe, Myriam ^a   Dougherty, Ryan H ^a   Dean, Nicholas M ^b   Gaarde, William A ^b   Holbrook, Nikki J ^a,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c GRC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PROTEIN P21; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION;

APOPTOSIS; CELL DIVISION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 9; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033969883     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.20.5.1713-1722.2000     Document Type: Article

References (44)

1. Angel, P., and M. Karin. 1991. The role of Jun, Fos, and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1072:129-157.
2. Antonyak, M. A., D. K. Moscatello, and A. J. Wong. 1998. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J. Biol. Chem. 273:2817-2822.
3. Behrens, A., M. Sibilia, and E. F. Wagner. 1999. Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat. Genet. 21:326-329.
4. Bost, F., N. Dean, R. McKay, and D. Mercola. 1997. Activation of the Jun kinase/stress-activated protein kinase pathway is required for EGF-autocrine stimulated growth of human A549 lung carcinoma cells. J. Biol. Chem. 272:33422-33429.
5. Bost, F., R. McKay, M. Bost, O. Potapova, N. Dean, and D. Mercola. 1919. Jun kinase-2 isoform is preferentially required for epidermal growth factor-induced proliferation of human A549 lung carcinoma. Mol. Cell. Biol. 19: 1938-1949.
6. Bost, F., O. Potapova, C. Liu, Y.-M. Yang, W. Charbono, N. Dean, R. McKay, and D. Mercola. 1999. High frequency regression of established human prostate carcinoma PC3 xenografts by systemic treatment with antisense Jun kinase. Prostate 38:321.
7. Brown, J. M., and B. G. Wouters. 1999. Apoptosis, p5.3. and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1391-1399.
8. Bunz, F., A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J. P. Brown, J. M. Sedivy, K. W. Kinzler, and B. Vogelstein. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501.
9. Chan, E. D., B. W. Winston, M. B. Jarpe, M. W. Wynes and D. W. Riches. 1997. Preferential activation of the p46 isoform of JNK/SAPK in mouse macrophages by TNF alpha. Proc. Natl. Acad. Sci. USA 94:13169-13174.
10. Church, G. M., and W. Gilbert. 1984. Genomic sequencing. Proc. Natl. Acad. Sci. USA 81:1991-1995.
11. Dean, N. M., R. McKay, T. P. Condon, and C. F. Bennett. 1994. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. 269:16146-16424.
12. Dérijard, B., M. Hibi, I. H. Wu, T. Barrett, B. Su, T. Deng, M. Karin, and R. J. Davis. 1994. JNKI: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-1037.
13. Dong, C., D. D. Yang, M. Wysk, A. J. Whitmarsh, R. J. Davis, and R. A. Flavell. 1998. Defective T cell differentiation in the absence of Jnk1. Science 282:2092-2095.
14. Fuchs, S. Y., L. R. Dolan, R. J. Davis, and Z. Ronai. 1996. JNK targets the ubiquitination of c-Jun in a phosphorylation dependent manner. Oncogene 13:1531-1535.
15. Fuchs, S. Y., V. Adler, T. Buschmann, Z. Yin, X. Wu, S. N. Jones, and Z. Ronai. 1998. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 12:2658-2663.
16. Fuchs, S. Y., V. Adler, M. R. Pincus, and Z. Ronai. 1998. MEKK1/JNK signaling stabilizes and activates p53. Proc. Natl. Acad. Sci. USA. 95:10541-10546.
17. Fuchs, S. Y., V. Fried, and Z. Ronai. 1998. Stress activated kinase regulates protein stability. Oncogene 12:2558-2563.
18. Gorospe, M., X. Wang, and N. J. Holbrook. 1998. p53-dependent elevation of p21Waf1 expression by UV light is mediated through mRNA stabilization and involves a vanadate-sensitive regulatory system. Mol. Cell. Biol. 18: 1400-1407.
19. Gorospe, M., X. Wang, and N. J. Holbrook, 1999. Functional role of p21 during the cellular response to stress. Gene Expression 7:337-385.
20. Gupta, S., T. Barrett, A. J. Whitmarsh, J. Cavanagh, H. K. Sluss, B. Dérijard, and R. J. Davis. 1996. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 15:2760-2770.
21. Hawkins, D. S., G. W. Demers, and D. A. Galloway. 1996. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56: 892-898.
22. Hibi, M., A. Lin, T. Smeal, A. Minden, and M. Karin. 1993. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev. 7:2135-3148.
23. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49-53.
24. Hu, M. C., W. R. Qiu, and Y. P. Wang. 1997. JNK1, JNK2 and JNK3 are p53 N-terminal serine 34 kinases. Oncogene 15:2277-2287.
25. Ip, Y. T., and R. J. Davis. 1998. Signal transduction by the c-Jun N-terminal kinase (JNK) from inflammation to development. Curr. Opin. Cell Biol. 10:205-219.
26. Kallunki, T., B. Su, I. Tsigelny, H. K. Sluss, B. Dérijard, G. Moore, R. Davis, and M. Karin. 1994. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev. 8:2996-3007.
27. Karin, M., Z. G. Liu, and E. Zandi. 1997. AP-1 function and regulation. Curr. Opin. Cell Biol. 9:240-246.
28. Kumagae, Y., Y. Zhang, O. J. Kim, and C. A. Miller. 1999. Human c-Jun N-terminal kinase expression and activation in the nervous system. Brain Res. Mol. Brain Res. 67:10-17.
29. Kyriakis, J. M., P. Banerjee, E. Nikolakaki, T. Dai, E. A. Rubie, M. F. Ahmad, J. Avruch, and J. R. Woodgett. 1994. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369:156-160.
30. Logan, S. K., M. Falasca, P. Hu, and J. Schlessinger. 1997. Phosphatidylinositol 3-kinase mediates epidermal growth factor-induced activation of the c-Jun N-terminal kinase signaling pathway. Mol. Cell. Biol. 7:5784-5790.
31. Lopez-Ilasaca, M., W. Li, A. Uren, J. C. Yu, A. Kazlauskas, J. S. Gutkind, and M. A. Heidaran, 1997. Requirement of phosphatidylinositol-3 kinase for activation of JNK/SAPKs by PDGF. Biochem. Biophys. Res. Commun. 232: 273-277.
32. Milne, D. M., L. E. Campbell, D. G. Campbell, and D. W. Meek. 1995. p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J. Biol. Chem. 279:5511-5518.
33. Minden, A., A. Lin, M. McMahon, C. Lange-Carter, B. Derijard, R. J. Davis, G. L. Johnson, and M. Karin. 1994. Differential activation of ERK and JNK mitoger-activated protein kinases by Raf-1 and MEKK. Science 266:1719-1723.
34. Minden, A., and M. Karin. 1997. Regulation and function of the JNK subgroup of MAP kinases. Biochim. Biophys. Acta 1333:F85-F104.
35. Mohit, A. A., J. H. Martin, and C. A. Miller. 1995. p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system. Neuron 14:67-78.
36. Raitano, A. B., J. R. Halpern, T. M. Hambuch, and C. L. Sawyers. 1995. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. USA 92:11746-11750.
37. Rodrigues, G. A., M. Park, and J. Schlissinger. 1997. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J. 16:2634-2645.
38. Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
39. Schreiber, M., A. Kolbus, F. Piu, A. Szabowski, U. Mohle-Steinlein, J. Tian, M. Karin, P. Angel, and E. F. Wagner. 1999. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 13:607-619.
40. Tsang, N. M., H. Nagasawa, C. Li, and J. B. Little. 1995. Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene 10:2403-2408.
41. Waldman, T., K. W. Kinzler, and B. Vogelstein. 1995. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:5187-5190.
42. Wisdom, R., R. S. Johnson, and C. Moore. 1999. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 18:188-197.
43. Xu, X. S., C. Vanderziel, C. F. Bennett, and B. P. Monia. 1998. A role for c-Raf kinase and Ha-Ras in cytokine-mediated induction of cell adhesion molecules. J. Biol. Chem. 273:33230-33238.
44. + T cell to Th1 cells requires MAP kinase JNK2. Cell 9:575-585.